INS and type 1 diabetes mellitus: Thirdly, the absolute differences in hypoglycemia incidence and, consequently, the pharmacoeconomic benefits of new insulins are low and may underestimate their effect in the broad type 1 diabetes population (Elliott et al., 2016).